TSX Exchange Symbol: RVX
CALGARY, June 22, 2015 /PRNewswire/ - Resverlogix
Corp. (TSX: RVX) today announced that following recent meetings
with various European regulatory bodies, the first confirmation for
our Phase 3 clinical plan has officially been received. A further
regulatory and protocol design update will be provided to the
market post the approval of additional regulatory bodies and the
launch of our planned Phase 3 clinical trial entitled
BETonMACE.
"This represents a momentous step forward in the clinical
development of RVX-208," stated Donald
McCaffrey, president and chief executive officer of
Resverlogix. "With this important regulatory confirmation now
complete, we expect to launch the upcoming BETonMACE Phase 3
clinical trial this fall. The primary endpoint of the BETonMACE
trial is designed to show a relative risk reduction (RRR) of Major
Adverse Cardiac Events (MACE) in high-risk cardiovascular and
diabetes mellitus (DM) patients, as we have seen in previous Phase
2 clinical trials with RVX-208," further stated Mr. McCaffrey.
About RVX-208
RVX-208 is a first-in-class, small molecule selective BET
bromodomain inhibitor. BET bromodomain inhibition is an epigenetic
mechanism that can turn disease-causing genes off, returning them
to a healthier state. RVX-208 is the first and only BET inhibitor
selective for BRD4-BD2, producing a nexus of biological effects
with potentially important benefits for patients with diseases such
as cardiovascular disease (CVD), diabetes mellitus (DM),
Alzheimer's disease, peripheral artery disease, and chronic kidney
disease while maintaining an excellent safety profile. Resverlogix
is planning to study RVX-208 in a proposed Phase 3 clinical trial
in CVD patients with DM and low HDL.
About Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small
molecule selective BET bromodomain inhibitor for the potential
treatment of patients with cardiovascular disease, diabetes
mellitus, Alzheimer's disease, peripheral artery disease, and
chronic kidney disease. RVX-208 is the only selective BET
bromodomain inhibitor in clinical trials. Resverlogix's common
shares trade on the Toronto Stock Exchange (TSX: RVX). For further
information please visit www.resverlogix.com. We can be
followed on our blog
at http://www.resverlogix.com/blog and via
Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to a Phase 3 clinical trial planned by the
Company, research and development activities and the potential role
of RVX-208 in the treatment of cardiovascular disease, diabetes
mellitus, Alzheimer's disease, peripheral artery disease, and
chronic kidney disease. Our actual results, events or developments
could be materially different from those expressed or implied by
these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our
Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR
at www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email:
don@resverlogix.com
Sarah Zapotichny
Director of Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com
SOURCE Resverlogix Corp.
